This Article Full Text Full Text (PDF) Other Versions of this Article: CVI.00039-07v1 14/7/830    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wedege, E. Articles by Martin, D. Search for Related Content PubMed PubMed Citation Articles by Wedege, E. Articles by Martin, D. Pubmed/NCBI databases Substance via MeSH

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, July 2007, p. 830-838, Vol. 14, No. 7
1071-412X/07/$08.00+0     doi:10.1128/CVI.00039-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Functional and Specific Antibody Responses in Adult Volunteers in New Zealand Who Were Given One of Two Different Meningococcal Serogroup B Outer Membrane Vesicle Vaccines

Norwegian Institute of Public Health, Department of Bacteriology and Immunology, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway,¹ The Institute of Environmental Science and Research Ltd., Wellington, New Zealand,² Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, 53100 Siena, Italy³

Received 18 January 2007/ Returned for modification 25 February 2007/ Accepted 25 April 2007

This study presents detailed analyses of total and specific serum antibody levels among 26 and 24 adult volunteers before vaccination and after the third dose of the meningococcal serogroup B outer membrane vesicle (OMV) vaccines MeNZB and MenBvac, respectively, in a clinical trial in New Zealand (V. Thornton, D. Lennon, K. Rasanathan, J. O'Hallahan, P. Oster, J. Stewart, S. Tilman, I. Aaberge, B. Feiring, H. Nokleby, E. Rosenqvist, K. White, S. Reid, K. Mulholland, M. J. Wakefield, and D. Martin, Vaccine 24:1395-1400, 2006). With the homologous vaccine strains as targets, both vaccines induced significant increases in serum bactericidal and opsonophagocytic activities and in the levels of immunoglobulin G (IgG) to OMV antigens in an enzyme-linked immunosorbent assay (ELISA) and to live meningococci by flow cytometry. They also induced high levels of activity against the heterologous strains, particularly in terms of opsonophagocytic activity and IgG binding to live bacteria. The antibody levels with the homologous and heterologous strains in the four assays showed high and significant positive correlations. Specific IgG binding to 10 major OMV antigens in each vaccine was measured by scanning of immunoblots; ELISAs for two antigens, lipopolysaccharide and Neisseria surface protein A (NspA), were also performed. Both vaccines elicited significant increases in IgG binding to all homologous and heterologous OMV antigens except NspA. The total IgG band intensity on the blots correlated significantly with the IgG levels determined by the OMV ELISA and flow cytometry. In conclusion, the results of the various immunological assays showed that both OMV vaccines gave rise to high levels of specific and cross-reacting antibodies.

Published ahead of print on 9 May 2007.

This article has been cited by other articles:

• Welsch, J. A., Granoff, D. (2007). Immunity to Neisseria meningitidis Group B in Adults despite Lack of Serum Bactericidal Antibody. CVI 14: 1596-1602 [Abstract] [Full Text]